NQO1 and neoplasm: Since the level of NQO1 in tumors varies in different individuals, an anticancer agent with the minimum affinity for NQO1 to be fully activated by the level of enzyme in the tumor of a patient would provide the maximum antitumor effect, while minimizing activation in the marrow and the resulting marrow toxicity for that individual.